Core Viewpoint - Vivos Therapeutics has announced a collaboration with SoundHealth to enhance public awareness and access to innovative airway and sleep health technologies, aiming to improve treatment for breathing-related sleep disorders [1][2][3] Group 1: Collaboration Details - The partnership will utilize Vivos' network of over 2,000 trained dentists and sleep healthcare providers to distribute SoundHealth's Sonu platform, which includes the FDA-cleared Sonu® Band and the new Spatial Sleep™ band [2][3] - Vivos will act as a reseller for SoundHealth's products, leveraging SoundHealth's extensive craniofacial dataset and technology for educational and distribution initiatives [3] Group 2: Product Information - The Sonu Band is the first FDA-cleared AI-enabled wearable for treating nasal congestion, comparable to intranasal steroids, and has no side effects [4] - The Spatial Sleep band uses personalized acoustic resonance therapy to promote rapid sleep onset and longer sleep duration through active neural entrainment [5] - Both devices utilize smartphone cameras to create a CT-quality anatomical model for personalized therapeutic stimulation [5] Group 3: Health Impact and Market Insights - The collaboration addresses significant health risks, as untreated sleep-disordered breathing is linked to a 140% increased risk of heart failure and a 30% higher risk of coronary heart disease [7] - The global sleep technology market is valued at approximately $30 billion, with a shift from passive tracking to active airway interventions, highlighting the need for better diagnosis and treatment of sleep disorders [8][9] - Over 1 billion people are affected by obstructive sleep apnea (OSA), with 80% remaining undiagnosed, indicating a substantial market opportunity for innovative treatments [11]